Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CING NASDAQ:GNPX NYSE:NNVC NASDAQ:PASG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCINGCingulate$3.99+1.3%$4.52$3.02▼$9.69$21.60M-0.76168,788 shs79,602 shsGNPXGENPREX$0.16-6.1%$0.24$0.14▼$3.97$5.49M-0.657.32 million shs2.63 million shsNNVCNanoViricides$1.39-1.8%$1.51$0.94▼$2.02$22.34M0.96238,649 shs109,378 shsPASGPassage Bio$7.13+3.3%$6.85$5.12▼$26.60$22.66M1.8228,890 shs20,864 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCINGCingulate0.00%-4.77%-22.97%+1.01%-50.13%GNPXGENPREX0.00%-2.55%-29.00%-53.80%-76.41%NNVCNanoViricides0.00%-3.47%-14.20%-8.55%-27.23%PASGPassage Bio0.00%-5.44%+11.06%-17.11%-49.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCINGCingulate2.3425 of 5 stars3.53.00.00.02.20.80.6GNPXGENPREX1.7993 of 5 stars0.03.00.04.73.80.00.6NNVCNanoViricides0.3956 of 5 stars0.05.00.00.01.50.00.0PASGPassage Bio3.846 of 5 stars3.55.00.00.03.32.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCINGCingulate 3.00Buy$26.25557.89% UpsideGNPXGENPREX 0.00N/AN/AN/ANNVCNanoViricides 0.00N/AN/AN/APASGPassage Bio 3.00Buy$91.751,186.82% UpsideCurrent Analyst Ratings BreakdownLatest GNPX, NNVC, CING, and PASG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/22/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$61.00 ➝ $62.008/14/2025PASGPassage BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$260.00 ➝ $67.008/13/2025PASGPassage BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$40.008/8/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/24/2025PASGPassage BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$120.00(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCINGCingulateN/AN/AN/AN/A$2.32 per shareN/AGNPXGENPREXN/AN/AN/AN/A$0.15 per shareN/ANNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/APASGPassage BioN/AN/AN/AN/A$19.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCINGCingulate-$15.55M-$4.100.00N/AN/AN/A-232.16%-132.07%11/6/2025 (Estimated)GNPXGENPREX-$21.11MN/A0.00N/AN/AN/A-809.27%-386.95%11/11/2025 (Estimated)NNVCNanoViricides-$8.29M-$0.70N/A∞N/AN/A-87.90%-78.69%N/APASGPassage Bio-$64.77M-$18.16N/AN/AN/AN/A-103.87%-59.95%11/12/2025 (Estimated)Latest GNPX, NNVC, CING, and PASG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025CINGCingulate-$0.82-$1.09-$0.27-$1.09N/AN/A8/14/2025Q2 2025GNPXGENPREX-$0.71-$0.17+$0.54-$0.17N/AN/A8/12/2025Q2 2025PASGPassage Bio-$4.00-$2.96+$1.04-$2.96N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCINGCingulateN/AN/AN/AN/AN/AGNPXGENPREXN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCINGCingulateN/A1.521.52GNPXGENPREXN/A0.840.84NNVCNanoViricidesN/A3.442.47PASGPassage BioN/A3.053.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCINGCingulate41.31%GNPXGENPREX14.05%NNVCNanoViricides10.30%PASGPassage Bio53.48%Insider OwnershipCompanyInsider OwnershipCINGCingulate4.04%GNPXGENPREX0.44%NNVCNanoViricides4.60%PASGPassage Bio4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCINGCingulate205.41 million5.19 millionNot OptionableGNPXGENPREX2033.47 million33.32 millionNo DataNNVCNanoViricides2016.07 million14.92 millionOptionablePASGPassage Bio1303.18 million3.04 millionOptionableGNPX, NNVC, CING, and PASG HeadlinesRecent News About These CompaniesPassage Bio to Participate in H.C. Wainwright 27th Annual Global Investment ConferenceAugust 28 at 7:00 AM | globenewswire.comPassage Bio (PASG) Receives a Buy from TD CowenAugust 15, 2025 | theglobeandmail.comWall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to TradeAugust 15, 2025 | zacks.comPassage Bio price target lowered to $67 from $260 at CanaccordAugust 14, 2025 | msn.comPassage Bio Reports Q2 2025 Progress and FinancialsAugust 13, 2025 | msn.comPassage Bio reports Q2 EPS ($2.96) vs ($5.09) last yearAugust 12, 2025 | msn.comPassage Bio Reports Promising Q2 2025 Financial ResultsAugust 12, 2025 | msn.comPassage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business HighlightsAugust 12, 2025 | globenewswire.comPassage Bio Regains Nasdaq Compliance with Stock PriceJuly 29, 2025 | tipranks.comInsider Buying: Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Acquires 13,123 Shares of StockJuly 25, 2025 | insidertrades.comPassage Bio Announces 1-for-20 Reverse Stock SplitJuly 10, 2025 | globenewswire.comPassage Bio, Inc. (PASG) Income Statement - Yahoo FinanceJuly 1, 2025 | finance.yahoo.comPASG Passage Bio, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comPassage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 138,800 SharesJune 27, 2025 | insidertrades.comPassage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program UpdateJune 23, 2025 | globenewswire.comPassage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy DevelopmentMay 17, 2025 | msn.comPassage Bio : résultat d'exploitation de -16,459 millions de dollars au premier trimestreMay 13, 2025 | zonebourse.comZPASSAGE BIO, INC. : Wedbush persiste à l'achatMay 13, 2025 | zonebourse.comZPassage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business HighlightsMay 13, 2025 | globenewswire.comInsider Selling: Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Sells 68,195 Shares of StockApril 25, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGrab Holdings: Get a Grip Now—Explosive Upside Brewing By Thomas Hughes | August 18, 2025Deeply Undervalued, Micron Technologies Stock Isn’t Pricing in AIBy Thomas Hughes | August 14, 2025Oklo’s Stock Is Set up for a Correction—Buy It When It BouncesBy Thomas Hughes | August 12, 2025Is Viking’s Growth Still Worth the Premium?By Chris Markoch | August 20, 2025Rigetti Stock: A Long-Term Quantum Play Facing Short-Term TestsBy Chris Markoch | August 13, 2025GNPX, NNVC, CING, and PASG Company DescriptionsCingulate NASDAQ:CING$3.99 +0.05 (+1.27%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.97 -0.02 (-0.50%) As of 08/29/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.GENPREX NASDAQ:GNPX$0.16 -0.01 (-6.12%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.16 0.00 (-0.61%) As of 08/29/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.NanoViricides NYSE:NNVC$1.39 -0.03 (-1.77%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$1.41 +0.02 (+1.44%) As of 08/29/2025 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.Passage Bio NASDAQ:PASG$7.13 +0.23 (+3.33%) Closing price 08/29/2025 03:51 PM EasternExtended Trading$6.98 -0.15 (-2.10%) As of 08/29/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
